Rayyan Alternatives for Systematic Reviews (2026) | Ponder.ing

Rayyan is a widely used AI-assisted screening tool for systematic reviews — it handles title/abstract screening with machine learning predictions, marks papers for inclusion or exclusion, tracks inter-rater agreement, and supports PRISMA-compatible exports. Its free tier covers basic screening, but the paid features (PICO extraction, advanced AI screening, PRISMA generator) require a subscription. Teams running large-volume reviews, Cochrane-aligned systematic reviews, or reviews requiring enterprise audit trails sometimes find better workflow fits elsewhere. These seven alternatives cover the spectrum from fully free open-source tools to enterprise-grade systematic review platforms.

Rayyan vs Its Alternatives: What You Are Choosing Between

All of these tools assist with systematic and scoping review workflows. The differences are in methodology alignment, ML screening capability, full-text data extraction, and what happens after screening is complete.

• Rayyan — AI-assisted title/abstract screening with inter-rater agreement tracking; free tier for basic screening; paid tier for PICO extraction and advanced AI features
• Covidence — the most widely adopted paid systematic review platform; Cochrane-aligned workflow; built-in data extraction and risk-of-bias tools
• Colandr — free open-source screening tool with active development; good for teams needing a Rayyan alternative without licensing costs
• EPPI-Reviewer — research-grade systematic review platform with ML-assisted text mining and complex synthesis features
• DistillerSR — enterprise systematic review software with full audit trails for regulatory and health technology assessment reviews
• Abstrackr — free ML-assisted abstract screening tool from Brown University; useful for automated priority ordering at no cost
• JBI SUMARI — systematic review platform aligned with Joanna Briggs Institute (JBI) methodology and reporting standards
• Ponder — not a screening tool; use it after screening is complete, to synthesise the full-text papers you have included in your review

Covidence — When You Need the Most Complete Cochrane-Aligned Systematic Review Platform

Covidence is the systematic review platform recommended by Cochrane and used by more systematic review teams than any other dedicated tool. Its workflow covers the complete review lifecycle: title/abstract screening, full-text screening, data extraction with customisable forms, risk-of-bias assessment (RoB 2.0 and other tools), and PRISMA-compatible reporting. Built-in conflict resolution for disagreements between reviewers, automatic deduplication, and direct integration with citation managers (Zotero, Mendeley, EndNote) make it the most workflow-complete option in this comparison.

How it differs from Rayyan: Rayyan is primarily a screening tool that does the title/abstract phase well. Covidence covers the full review workflow from import through data extraction and risk-of-bias to reporting — Rayyan requires additional tools for those phases. Covidence's data extraction forms are built-in and customisable; Rayyan's extraction is either manual or paid-tier AI. Covidence is paid from the start (no meaningful free tier for reviews at scale); Rayyan's free tier is more accessible for small teams. For systematic reviews that will be submitted to Cochrane or high-quality systematic review journals, Covidence's methodology alignment is a practical requirement.

• Cochrane-official systematic review platform with full methodology support
• Complete workflow: import → deduplication → screening → extraction → risk-of-bias → reporting
• Customisable data extraction forms with populated and calculated fields
• RoB 2.0 and other validated risk-of-bias assessment tools built-in
• PRISMA flow diagram generation and reporting checklist support
• Per-review pricing model; institutional licensing also available

Colandr — When Your Team Needs a Free Open-Source Screening Tool

Colandr is a free open-source systematic review screening platform actively developed with NSF and NIH support. It provides title/abstract screening with ML-assisted relevance predictions, team collaboration with inter-rater agreement tracking, full-text screening, and PRISMA export — covering Rayyan's core features without licensing costs. Following a major 2026 update improving its ML screening engine and collaboration features, Colandr has become a stronger direct alternative for teams that cannot afford Rayyan's paid tier or Covidence's per-review costs.

How it differs from Rayyan: Colandr is fully free and open-source; Rayyan's advanced features require a paid subscription. Rayyan's interface is more polished and its ML screening support is more mature. Colandr's active development and academic funding model gives it long-term sustainability as a free tool without future paywall risk. For teams doing systematic reviews with budget constraints — academic teams, public health researchers, students — Colandr covers the core screening workflow at zero cost. Colandr currently does not include built-in data extraction forms, which Rayyan's paid tier adds.

• Completely free and open-source — no subscription, no per-review cost
• ML-assisted abstract screening with relevance predictions and priority ordering
• Team screening with inter-rater agreement tracking and conflict resolution
• Full-text screening alongside title/abstract workflow
• PRISMA-compatible export for reporting
• Developed with NSF and NIH research support — stable free model

EPPI-Reviewer — When You Need ML-Assisted Text Mining and Complex Synthesis

EPPI-Reviewer from the EPPI-Centre at UCL is a research-grade systematic review platform with capabilities that go substantially beyond Rayyan's screening focus. Its text mining and ML tools automate not just abstract screening but also concept extraction, thematic coding, and synthesis tasks that typically require manual effort. EPPI-Reviewer handles complex mixed-methods reviews, qualitative evidence synthesis, and realist reviews — review types that other tools are not designed for. It is used by public health agencies, NICE in the UK, and major research funders for high-stakes evidence reviews.

How it differs from Rayyan: Rayyan is optimised for the title/abstract screening phase. EPPI-Reviewer is optimised for the entire complex review synthesis workflow, including qualitative and mixed-methods synthesis types that Rayyan does not support. EPPI-Reviewer's ML tools extend to concept extraction and data synthesis in ways that go beyond screening predictions. For standard systematic reviews, Rayyan's interface is simpler and faster to set up; for complex qualitative synthesis or mixed-methods reviews, EPPI-Reviewer's capabilities are necessary rather than optional.

• ML-assisted text mining for concept extraction beyond abstract screening
• Qualitative evidence synthesis and mixed-methods review support
• Advanced coding and thematic analysis tools within the platform
• Used by NICE, WHO, and major health research funders
• More complex setup than Rayyan; designed for methodologically sophisticated reviews
• Institutional licensing through UCL; pricing available via EPPI-Centre

DistillerSR — When Your Review Requires Enterprise Audit Trails and Regulatory Evidence Standards

DistillerSR is an enterprise systematic review platform built for regulatory evidence synthesis: health technology assessments (HTAs), medical device dossiers, and pharmaceutical regulatory submissions where full audit trail documentation is a requirement. It provides complete traceability for every screening and extraction decision — who made the decision, when, and based on what criteria — with electronic signature capabilities and configurable access controls. For academic systematic reviews, this level of auditing is usually unnecessary; for regulatory submissions, it is required.

How it differs from Rayyan: Rayyan's audience is academic researchers and systematic review teams; DistillerSR's primary audience is the regulatory and HTA community requiring compliance-grade documentation. DistillerSR's pricing reflects enterprise positioning and is significantly above Rayyan's. For academic systematic reviews, Rayyan or Covidence provide equivalent screening quality without the compliance overhead. For pharmaceutical, device, or health technology assessment submissions requiring documented audit trails, DistillerSR provides a workflow that Rayyan does not match.

• Full audit trail for every screening and extraction decision with user attribution
• Electronic signature and access control for regulated review environments
• Validated for pharmaceutical and HTA regulatory submission requirements
• Configurable quality control and data verification workflows
• Integration with regulatory document management systems
• Enterprise pricing; designed for HTA bodies, CROs, and pharmaceutical teams

Abstrackr — When You Need Free ML-Assisted Abstract Screening Without a Subscription

Abstrackr is a free abstract screening tool developed by Brown University that uses machine learning to prioritise abstracts for human review. It predicts which abstracts are most likely to be relevant based on your initial inclusion decisions, reordering the queue so that reviewers encounter the likely-relevant papers first — a prioritisation that can substantially reduce the number of abstracts that need to be reviewed before the relevant set is captured. The tool is web-based, requires no installation, and has no usage limits or subscription.

How it differs from Rayyan: Abstrackr covers a narrower slice of the review workflow than Rayyan — it handles abstract screening and prioritisation but does not provide data extraction, risk-of-bias tools, or full-text management. Rayyan's interface is more polished and its workflow is more complete; Abstrackr's only differentiator is cost (completely free) and the priority-ordering ML model that is particularly effective for large-volume screening. For systematic reviews with thousands of abstracts to screen and no budget for paid tools, Abstrackr's ML prioritisation can meaningfully reduce reviewer burden.

• Completely free — no subscription, no account required for basic use
• ML-based abstract priority ordering — most likely relevant papers screened first
• Reduces screening burden by enabling reviewers to stop before exhausting the full set
• Developed and maintained by Brown University's evidence synthesis team
• Limited to abstract screening — no data extraction or risk-of-bias features
• Web-based with no installation required

JBI SUMARI — When Your Review Must Follow JBI Methodology and Reporting Standards

JBI SUMARI (System for the Unified Management, Assessment and Review of Information) is the systematic review platform built and maintained by the Joanna Briggs Institute. For reviews that will be submitted to JBI Evidence Synthesis or need to follow JBI's specific methodology (which differs from Cochrane in several respects — particularly for mixed-methods and qualitative reviews), SUMARI provides the aligned workflow and tools. It provides critical appraisal tools specific to JBI's appraisal checklists and synthesis approaches not supported by platforms built for Cochrane methodology.

How it differs from Rayyan: Rayyan is methodology-agnostic for screening. JBI SUMARI is methodology-specific for JBI-aligned reviews — it includes JBI's critical appraisal checklists, evidence tables, and synthesis documentation. For Cochrane-aligned reviews, Covidence is the better fit. For JBI-aligned reviews, SUMARI is the required tool rather than an optional alternative. For reviews that don't need to follow a specific methodology body's requirements, Rayyan or Covidence are simpler. JBI membership or institutional affiliation with JBI is typically required for SUMARI access.

• Built and maintained by the Joanna Briggs Institute for JBI-methodology reviews
• JBI critical appraisal checklists for all study types integrated into the platform
• Supports mixed-methods and qualitative synthesis types aligned with JBI approach
• Evidence tables and synthesis documentation following JBI reporting standards
• Required for systematic reviews submitted to JBI Evidence Synthesis journal
• Access through JBI membership or institutional affiliation

Ponder — For Synthesising the Full-Text Papers After Screening Is Complete

Ponder is not a screening tool. It is an AI research synthesis platform — the workflow phase that comes after systematic review screening is complete. Once you have used Rayyan, Covidence, or Colandr to identify which papers are included in your review, Ponder lets you import those included papers, run multi-document Q&A across the full text, extract structured comparisons across studies, and build an evidence synthesis with page-level citations rather than manually reading each paper.

How it differs from Rayyan: Rayyan handles the screening phase — deciding which papers to include. Ponder handles the synthesis phase — understanding what those included papers actually say across the full text. Rayyan's AI predictions help you include the right papers; Ponder's AI helps you understand and synthesise them after inclusion. For systematic reviewers whose bottleneck is not screening time but synthesis time — reading, comparing, and extracting from dozens of included studies — Ponder's multi-document Q&A layer reduces that burden with page-level citations.

• AI Q&A synthesising across your entire set of included papers simultaneously
• Page-level citations in every answer — traceable to source document and page
• Structured comparison extraction across included studies
• Import PDFs from any source including Rayyan, Covidence, or Zotero exports
• Academic Search powered by OpenAlex: 250M+ papers for finding additional sources
• Free tier: 50 credits/day; Casual $14/month; Pro $42/month

What Rayyan Does That These Alternatives Don't

Rayyan's combination of a generous free tier for basic screening, a polished interface, mobile apps for screening on the go, and AI-assisted screening predictions across title/abstract and full text in a single workflow is not precisely replicated by any alternative at the same price point. Covidence is more complete but paid from the start. Colandr is free but less polished. Abstrackr has stronger ML prioritisation for large-volume screening but covers only abstract triage. JBI SUMARI and DistillerSR are methodology- or compliance-specific. Rayyan's broad middle ground — accessible enough for student projects, capable enough for published systematic reviews — is its core differentiator.

• Free tier for real-use screening — title/abstract screening at no cost with no paper limit; Covidence charges per review, DistillerSR is enterprise-priced, and Abstrackr is free but narrower
• Mobile and web apps — screening on iPhone and Android apps in addition to the web; no other tool in this list provides native mobile screening
• PICO extraction in the paid tier — AI-assisted extraction of population, intervention, comparison, and outcome from abstracts; no free alternative offers this level of AI extraction assistance
• Broad methodology compatibility — works for Cochrane, Campbell, and custom systematic review approaches without methodology-specific constraints that limit JBI SUMARI and EPPI-Reviewer

Frequently asked questions

What is the best free alternative to Rayyan?

Colandr is the best like-for-like free alternative — it provides title/abstract screening, ML-assisted relevance predictions, inter-rater agreement tracking, and PRISMA export at no cost. Abstrackr is the best free option specifically for ML-prioritised large-volume abstract screening; it covers a narrower use case but its prioritisation algorithm is well-validated. For teams that need the full systematic review workflow (screening through extraction through risk-of-bias) at no cost, Colandr covers the screening phase and Ponder covers the synthesis phase together as a free combination.

Is Covidence better than Rayyan?

Covidence is more complete than Rayyan for the full systematic review workflow — it covers screening, full-text review, data extraction, risk-of-bias assessment, and PRISMA reporting in a single integrated platform. Rayyan is primarily a screening tool and requires additional tools for extraction and synthesis. Covidence is paid with no meaningful free tier; Rayyan's free tier covers basic screening. For published systematic reviews that will need to report a complete PRISMA pathway, Covidence's integrated workflow is a practical advantage. For quick screening projects, student reviews, or scoping reviews where basic screening is all that's needed, Rayyan's free tier is more accessible.

What tool should I use after finishing screening in Rayyan?

Ponder handles the synthesis phase that follows screening. Once you have determined your included studies in Rayyan, export and import those papers into Ponder to run AI-powered multi-document Q&A across the full text of your included studies. Rather than reading each paper sequentially to extract findings, you ask questions across the entire included set simultaneously and get structured answers with page-level citations. Ponder's free tier (50 credits/day) covers moderate synthesis workloads without additional cost.